Axsome Therapeutics price target raised to $140 from $138 at RBC Capital
RBC Capital raised the firm’s price target on Axsome Therapeutics (AXSM) to $140 from $138 and keeps an Outperform rating on the shares as part ...
Axsome Therapeutics: Strong Buy Recommendation Driven by Promising Pipeline and Market Expansion
Needham analyst Ami Fadia maintained a Buy rating on Axsome Therapeutics (AXSM – Research Report) today and set a price target of $133.00.Don't ...
BioSpace1d
Biopharma Heads to JP Morgan Seeking an M&A Spark to Improve Sentiment
M&A didn’t return as hoped for in 2024. The biopharma industry is heading into the J.P. Morgan Healthcare Conference next ...
The Pharma Letter2d
The week in pharma: action, reaction and insight – week to January 3
Among significant news in a holiday spattered week, Dutch biotech argenx gained another approval in Japan for its Vyvdura ...
alzheimersnewstoday4d
Axsome to ask FDA to approve AXS-05 for Alzheimer’s agitation
The company recently announced results from two Phase 3 trials of AXS-05 for agitation. ACCORD-2, hit its main goal, but ...
Alzheimer’s Drug Study Yields Mixed Results. Wall Street Still Likes Axsome.
In one study, the company’s drug eased the agitation for Alzheimer’s patients. In a different study, there wasn’t a ...
Investor's Business Daily on MSN4d
Neumora Therapeutics Stock Crashes 83% After Depression Drug Flops
Neumora Therapeutics stock collapsed Thursday after its experimental depression treatment failed in the first of three ...
BioSpace5d
Axsome Posts Mixed Phase III Data in Alzheimer’s Agitation, Plans FDA Filing
With two earlier trials meeting their primary endpoints, Axsome claimed it has the data to support a filing for FDA approval ...
bovnews6d
Stock Shock: The Unpredictable Rise and Fall of AXSM—What’s Driving the Drama?
Axsome Therapeutics Inc (AXSM) stock saw a decline, ending the day at $84.78 which represents a decrease of $-1.92 or -2.21% from the prior close of $86.7. The stock opened at $82 and touched a low of ...